Scarica l'app Stockscreener
3.87
0.26%
0.01
Pre-mercato:
4.02
0.15
+3.88%
Precedente Chiudi:
$3.86
Aprire:
$4.07
Volume 24 ore:
18,801
Relative Volume:
3.14
Capitalizzazione di mercato:
$193.51M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-5.2718
EPS:
-0.7341
Flusso di cassa netto:
-
1 W Prestazione:
-8.64%
1M Prestazione:
-5.11%
6M Prestazione:
-9.54%
1 anno Prestazione:
-34.18%
Intervallo 1D:
$3.75
$4.10
Intervallo di 1 settimana:
$3.645
$4.24
Portata 52W:
$2.55
$6.0298
Genfit Adr Stock (GNFT) Company Profile
Confronta GNFT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GNFT
Genfit Adr
|
3.87 | 193.01M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Genfit Adr Stock (GNFT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-19 | Ripresa | H.C. Wainwright | Buy |
| 2021-12-20 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-07-23 | Aggiornamento | Stifel | Hold → Buy |
| 2020-06-25 | Iniziato | BofA/Merrill | Underperform |
| 2020-05-13 | Downgrade | Kepler | Buy → Reduce |
| 2020-05-12 | Downgrade | Barclays | Overweight → Equal Weight |
| 2020-05-12 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2019-10-29 | Reiterato | B. Riley FBR | Buy |
| 2019-06-25 | Iniziato | Stifel | Hold |
| 2019-04-24 | Iniziato | SVB Leerink | Outperform |
| 2019-04-22 | Iniziato | Barclays | Overweight |
Mostra tutto
Genfit Adr Borsa (GNFT) Ultime notizie
European ADRs Start The Week With Small Gains Stateside - Finimize
FY2025 Earnings Estimate for GENFIT Issued By HC Wainwright - Defense World
FY2025 EPS Estimates for GENFIT Lifted by Leerink Partnrs - Defense World
HC Wainwright Has Pessimistic View of GENFIT FY2025 Earnings - MarketBeat
GENFIT (NASDAQ:GNFT) Price Target Lowered to $7.00 at HC Wainwright - Defense World
HC Wainwright Has Lowered Expectations for GENFIT (NASDAQ:GNFT) Stock Price - MarketBeat
European ADRs Dip Slightly As Biotech Stocks Jump And Drop - Finimize
GENFIT (NASDAQ:GNFT) Coverage Initiated by Analysts at HC Wainwright - Defense World
European Biopharma ADRs: A Strategic Play in a Volatile Market - AInvest
European ADRs Tick Up As Pharma And Telecom Lead Gains - Finimize
GENFIT (NASDAQ:GNFT) Shares Up 0.7% – Time to Buy? - Defense World
European ADRs: Navigating Sectoral Divergence in a Volatile Market - AInvest
European Biopharma Leads Gains In ADR Market Surge - Finimize
European Biotech ADRs Lead the Charge: A Sector on the Verge of Breakthrough Growth - AInvest
European ADRs Show Strength With Genfit And Novo Nordisk Leading Gains - Finimize
European ADRs Show Optimism As Genfit Leads Gains - Finimize
European ADRs See Mixed Results With Modest Gains - Finimize
European ADRs Climb As Biopharmaceuticals Lead The Charge - Finimize
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Higher in Monday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Remain Flat for Week - TradingView
Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis - GlobeNewswire
symbol__ Stock Quote Price and Forecast - CNN
Ipsen confirms U.S. FDA grants priority review for New Drug - GlobeNewswire
Results from Ipsen’s ELATIVE® pivotal Phase III trial of - GlobeNewswire
Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease - Ipsen
Ipsen and GENFIT Enter Into Exclusive Licensing Agreement for Elafibranor, a Phase III Asset Evaluated in Primary Biliary Cholangitis, as Part of a Long-Term Global Partnership - Business Wire
Should I buy GENFIT (GNFT) - Zacks Investment Research
GNFT: GENFITFull Company Report - Zacks Investment Research
Genfit Adr Azioni (GNFT) Dati Finanziari
Non sono disponibili dati finanziari per Genfit Adr (GNFT). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.64%
0.35%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):